GLUEMonte Rosa Therapeutics Inc
$23.85
$0.17
(0.71%)
Pre-Market
EarningsAug 6
Mkt Cap$2.04B
Vol4,046.00
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
Key PointsThe chief medical officer of Monte Rosa Therapeutics reported selling 41,845 shares directly for a transaction value of approximately $882,000, based on a weighted average price of around $21.08 per share over June 23-24, 2026...
Nasdaq News: Markets
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday
Monte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-monte-rosa-therapeutics-inc-stock...
MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totaling 15,837,633 shares...
MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating an...
MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 22.2%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling...
MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $103,398.05 in Stock
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction on Thursday, April 9th. The shares were sold at an average...
MarketBeat
Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The shares were sold...
MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat...
MarketBeat
<
1
2
...
>